Foresite Capital

Today we’re pleased to announce our $225 million oversubscribed Series B financing round. The syndicate was led by General Atlantic, with participation from funds and accounts advised by T. Rowe Price Associates, Inc., Foresite Capital, The Invus Group, Goldman Sachs Alternatives, CPP Investments, and other new investors. Founding investors ARCH Venture Partners, Third Rock Ventures, and co-founder PureTech Health also participated. We’re proud to partner with this group of new and existing investors who share our commitment of delivering better medicines for those suffering from #depression, #anxiety and other #neuropsychiatric disorders. The proceeds will be used to advance our clinical-stage pipeline of first and best-in-class medicines through important clinical milestones as well as further advance the capabilities of our Glyph™ technology platform. https://bwnews.pr/4eQ6FHm

BREAKING NEWS The Royal Swedish Academy of Sciences has decided to award the 2024 Nobel Prize in Chemistry with one half to David Baker “for computational protein design” and the other half jointly to Demis Hassabis and John M. Jumper “for protein structure prediction.”   The Nobel Prize in Chemistry 2024 is about proteins, life’s ingenious chemical tools. David Baker has succeeded with the almost impossible feat of building entirely new kinds of proteins. Demis Hassabis and John Jumper have developed an AI model to solve a 50-year-old problem: predicting proteins’ complex structures. These discoveries hold enormous potential.   The diversity of life testifies to proteins’ amazing capacity as chemical tools. They control and drive all the chemical reactions that together are the basis of life. Proteins also function as hormones, signal substances, antibodies and the building blocks of different tissues.   Proteins generally consist of 20 different amino acids, which can be described as life’s building blocks. In 2003, David Baker succeeded in using these blocks to design a new protein that was unlike any other protein. Since then, his research group has produced one imaginative protein creation after another, including proteins that can be used as pharmaceuticals, vaccines, nanomaterials and tiny sensors.   The second discovery concerns the prediction of protein structures. In proteins, amino acids are linked together in long strings that fold up to make a three-dimensional structure, which is decisive for the protein’s function. Since the 1970s, researchers had tried to predict protein structures from amino acid sequences, but this was notoriously difficult. However, four years ago, there was a stunning breakthrough.   In 2020, Demis Hassabis and John Jumper presented an AI model called AlphaFold2. With its help, they have been able to predict the structure of virtually all the 200 million proteins that researchers have identified. Since their breakthrough, AlphaFold2 has been used by more than two million people from 190 countries. Among a myriad of scientific applications, researchers can now better understand antibiotic resistance and create images of enzymes that can decompose plastic.   Life could not exist without proteins. That we can now predict protein structures and design our own proteins confers the greatest benefit to humankind. Learn more Press release: https://bit.ly/3TM8oVs Popular information: https://bit.ly/3XYHZGp Advanced information: https://bit.ly/4ewMBta

Wow! Thank you to LinkedIn for naming Xaira Therapeutics one of 2024’s Top Startups in the United States! ✨ This recognition is especially meaningful because it's based on interaction with our page. You like us, you really like us! Thank you also to all the Xairanauts who are the heart, soul and explorers behind our mission. #AI #Healthcare #XairaTherapeutics #Biotech #LinkedInTopStartups2024 #checkthisoutmom!

⏳ The clock is ticking! This is the LAST WEEK for VCs to volunteer as mentors for VC University. We still need life science VC investors (of all experience levels) to volunteer. The time commitment is only 1 hour/month from November-January. By serving as a mentor to one of 40 VC University scholarship recipients – an aspiring and early-career VC from an underrepresented background – you can help advance a stronger, more inclusive venture ecosystem. Sign up by this Friday, Sept. 20: https://lnkd.in/gB6M7Y3t

I am thrilled to have been selected by MIT Technology Review as one of the 35 Innovators Under 35 worldwide! #ImmuneDictionary #CytokinesPower Excited to join this incredible community of innovators pushing the boundaries in science and technology. #BigData in #Immunology is coming of age, illuminating the elegance and complexity of our immune system in ways never before possible. I'm grateful to be part of this revolution, and looking forward to continuing to push the boundaries of #immunotherapies in the years ahead.

What’s the future of pregnancy health look like? Caltech's Techer details Mirvie CEO and co-founder Maneesh Jain’s journey to push the field of pregnancy health into the 21st century by using #RNA to predict pregnancy complications months in advance. Read more on how Mirvie is modernizing #maternalhealth here: https://lnkd.in/gUqQs-89

We are excited to announce the appointment of Tim Lugo as our new Chief Financial Officer and the addition of Beth Seidenberg, M.D., and Jim Tananbaum, M.D., to our board of directors. Tim brings over two decades of experience in biotechnology finance and equity research, while Dr. Seidenberg and Dr. Tananbaum are seasoned venture capitalists. Their expertise will be instrumental as we scale and accelerate the development of our non-opioid pain medicines. Welcome to the Latigo Biotherapeutics, Inc. team! Click the link below to read the full press release. 👇 https://lnkd.in/gHJFupPx #NonOpioidPainRelief #Leadership #BioPharma